Healthcare insurers like UnitedHealth Group Incorporated and Centene Corporation have suffered steep stock declines due to surging medical costs and regulatory headwinds. Both firms face rising cla...

UnitedHealth is deeply undervalued, trading at low P/E and P/FCF multiples despite long-term growth potential and a wide economic moat. Short-term challenges persist: earnings are down, CEO resigne...

Shares of UnitedHealth Group (NYSE: UNH) rose 1.2% to $240 on Monday, though the stock remains down 52% year-to-date.

UnitedHealth reported Q2-FY25 revenue of $111.6 billion, up 12.9% YoY, driven by UnitedHealthcare and Optum divisions. A $6.5 billion medical cost overrun led to a sharp rise in MCR to 89.4% and cu...

UnitedHealth Group's stock has suffered a steep decline, dropping from around $600 in April of this year to its current price near $260 — an astonishing 58% decrease over four months. This signific...

Despite missing Q2 2025 earnings expectations, I see potential in the company's valuation for future growth and profitability. I approach the analysis from a more abstract perspective, focusing on ...

UNH's oversold status has been overly done, as the market digests the market-wide headwinds arising from regulatory changes and macro uncertainties. While the management's new FY2025 guidance impli...

NEW YORK, Aug. 02, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against UnitedHeal...

UnitedHealth (UNH -4.78%) revised its annual targets, disappointing stock market investors.

On July 16, I wrote an article on UnitedHealth, rating it a buy (albeit a low-conviction buy with many risk factors). Yesterday, the company put out an earnings release that was worse than I antici...

Despite rising medical costs and margin pressures, UnitedHealth Group Incorporated remains solidly profitable, with strong sales growth and a robust net earnings base. UNH stock is now technically ...

Steve Weiss, Founder and Managing Partner of Short Hills Capital Partners joins CNBC's “Halftime Report” to detail his latest portfolio moves.

UnitedHealth's (NYSE: UNH) turbulent run in 2025 is escalating after the firm reported disappointing Q2 earnings results, but an AI platform has identified strategic entry points for long-term inve...

Returning CEO Stephen Hemsley is lowering expectations, but perhaps not enough.

Despite a double earnings miss, I am upgrading UnitedHealth Group Incorporated stock to Strong Buy due to its long-term growth potential and resilient fundamentals. UNH's current valuation prices i...